» Articles » PMID: 15064862

Role of Epigenetic Changes in Hematological Malignancies

Overview
Journal Ann Hematol
Specialty Hematology
Date 2004 Apr 6
PMID 15064862
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Inactivation of tumor suppressor genes is an important event contributing to the development of neoplasia. In addition to the classic genetic mechanisms of deletion or inactivating point mutations, growth regulatory genes can be functionally inactivated without alterations of the primary sequence by methylation of cytosine residues in the promoter regions of the genes. After introducing epigenetic phenomena in general and the molecular basis of DNA methylation in more detail, this review will present the broad spectrum of alterations in DNA methylation patterns found in hematopoietic malignancies. In addition, the implications for therapy and prognosis will be discussed.

Citing Articles

Small molecule-induced epigenomic reprogramming of APL blasts leading to antiviral-like response and c-MYC downregulation.

Amatori S, Persico G, Cantatore F, Rusin M, Formica M, Giorgi L Cancer Gene Ther. 2022; 30(5):671-682.

PMID: 36536122 PMC: 10191840. DOI: 10.1038/s41417-022-00576-w.


Bioinformatics analysis of the network of histone H3 lysine 9 trimethylation in acute myeloid leukaemia.

Dong A, Yang W, Huang H, Zhou X, He Z, Yao R Oncol Rep. 2020; 44(2):543-554.

PMID: 32468066 PMC: 7336454. DOI: 10.3892/or.2020.7627.


The Emerging Role of H3K9me3 as a Potential Therapeutic Target in Acute Myeloid Leukemia.

Monaghan L, Massett M, Bunschoten R, Hoose A, Pirvan P, Liskamp R Front Oncol. 2019; 9:705.

PMID: 31428579 PMC: 6687838. DOI: 10.3389/fonc.2019.00705.


DNA methylation profile in chronic myelomonocytic leukemia associates with distinct clinical, biological and genetic features.

Palomo L, Malinverni R, Cabezon M, Xicoy B, Arnan M, Coll R Epigenetics. 2017; 13(1):8-18.

PMID: 29160764 PMC: 5837079. DOI: 10.1080/15592294.2017.1405199.


Aberrant DNA Methylation Is Associated with a Poor Outcome in Juvenile Myelomonocytic Leukemia.

Sakaguchi H, Muramatsu H, Okuno Y, Makishima H, Xu Y, Furukawa-Hibi Y PLoS One. 2016; 10(12):e0145394.

PMID: 26720758 PMC: 4697810. DOI: 10.1371/journal.pone.0145394.